• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>McMoRan Exploration

McMoRan Exploration

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial

    ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial

  2. New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers

    New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers

  3. You and the Monetary System

    This article represents opinions of the author and not those of his firm and are subject to change from time to time and do not constitute a recommendation to purchase and sale any security nor to engage in any particular investment strategy. The information contained here has been obtained from ...

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.